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Original Article - Sexual Dysfunction
Nonresponders to Daily Paroxetine and Another SSRI in Men With 
Lifelong Premature Ejaculation: A Pharmacokinetic 
Dose-Escalation Study for a Rare Phenomenon
Paddy KC Janssen1,2, Daan Touw3, Dave H. Schweitzer4, Marcel D. Waldinger1,5
1Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of BetaSciences, Utrecht University, Utrecht, 
2Department of Central Hospital Pharmacy, Viecuri Hospital, Venlo, 3Apotheek Haagse Ziekenhuizen, HagaZiekenhuis, Den Haag, 
4Department of Internal Medicine and Endocrinology, Reinier de Graaf Groep of Hospitals, Delft-Voorburg, 5Department of Neurosexology, 
HagaZiekenhuis, Den Haag, The Netherlands
Purpose: Nonresponse to any selective serotonin reuptake inhibitor (SSRI) treatment 
is rare. In this study, we aimed to investigate ejaculation delay nonresponse to parox-
etine treatment in men with lifelong premature ejaculation (PE) who were also known 
to be nonresponders to other SSRIs. 
Materials and Methods: Five males with lifelong PE who were known nonresponders 
to paroxetine and other serotonergic antidepressants and eight males with lifelong PE 
who were specifically recruited were included. Blood sampling occurred 1 month and 
1 day before the start of treatment and at the end of three consecutive series of 4 weeks 
of daily treatment with 10-, 20-, and 30-mg paroxetine, respectively. Blood samples for 
measurement of leptin and paroxetine were taken at 8:30 AM, 9:30 AM, 10:30 AM, and 
11:30 AM, respectively. At 9:00 AM, one tablet of 10-, 20-, or 30-mg paroxetine was taken 
during the first, second, and third month, respectively. Intravaginal ejaculatory latency 
time (IELT) was measured with a stopwatch. The main outcome measures were the fold 
increase in the geometric mean IELT, serum leptin and paroxetine concentrations, body 
mass index (BMI), 5-HT1A receptor C-1019G polymorphism, and CYP2D6 mutations.
Results: Between the 7 paroxetine responders and 6 nonresponders, the fold increase 
in the geometric mean IELT was significantly different after daily 10-mg (p=0.003), 
20-mg (p=0.002), and 30-mg paroxetine (p=0.026) and ranged from 2.0 to 8.8 and from 
1.1 to 1.7, respectively. BMI at baseline and at the end of the study was not significantly 
different between responders and nonresponders. Serum leptin levels at baseline were 
similar in responders and nonresponders and did not change during treatment. The 
serum paroxetine concentration increased with increasing dosage and was not sig-
nificantly different between responders and nonresponders. There was no association 
between the fold increase in the geometric mean IELT and serum paroxetine levels dur-
ing the three treatment periods nor between leptin levels during the treatment periods 
and serum paroxetine levels. For the 5-HT1A receptor C-1019G variation, all responders 
had the CC genotype and all nonresponders had the GC genotype, respectively. 
Conclusions: Complete absence of paroxetine-induced ejaculation delay is presumably re-
lated to pharmacodynamic factors and perhaps to 5-HT1A receptor gene polymorphism.
Keywords: 5-HT1A (C-1019G) polymorphism; CYP2D6; Leptin; Lifelong premature 
ejaculation; Paroxetine hemihydrate
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INTRODUCTION
Daily use of selective serotonin reuptake inhibitors 
(SSRIs) very effectively delays ejaculation in men with life-
long premature ejaculation (PE) [1]. Compared to the other 
SSRIs, daily use of 20-mg paroxetine hemihydrate exerts 
the strongest ejaculation delay [1]. However, this is not al-
ways the case. The extent of ejaculation delay differs be-
tween men. For example, in a stopwatch study of 54 men 
with lifelong PE that investigated the association between 
paroxetine-induced ejaculation delay and the 5-HTTLPR 
polymorphism [2], 43 men (80%) responded with an ejacu-
lation delay, whereas 11 (20%) did not. A similar result was 
found by Salonia et al. [3] in a group of 65 men with lifelong 
PE with an estimated intravaginal ejaculatory latency 
time (IELT) of less than 1 minute. Of these patients, 15 men 
(23%) discontinued daily paroxetine treatment within 3 
months because the ejaculation delay was below expect-
ation, e.g., paroxetine had a minimal ejaculation delaying 
effect [3]. 
In rather rare cases, men with lifelong PE do not respond 
to any SSRI treatment with an ejaculation delay. This phe-
nomenon has so far not been mentioned in the literature 
of PE and has never been investigated. Theoretically, ul-
traextensive metabolizers of paroxetine may not respond 
with an ejaculation delay because an adequate paroxetine 
concentration may not be established [4]. Apart from this 
potential pharmacokinetic factor, animal studies have also 
shown that pharmacodynamic factors, such as the amount 
of serotonin neurotransmission and/or 5-HT1A receptor ac-
tivation, are associated with the extent of ejaculation delay 
[5,6]. However, whether pharmacokinetic or pharmacody-
namic factors may explain the (nearly) complete absence 
of SSRI-induced ejaculation delay in some men with life-
long PE remains unknown. It is of note that SSRI-induced 
ejaculation delay has been suggested to be related to de-
creased serum leptin levels [7] and that there is a relation-
ship between serum plasma testosterone levels and the se-
rum leptin level [8]. 
The aim of the current study was to investigate the role 
of various pharmacokinetic factors (e.g., paroxetine dos-
age, serum paroxetine level, Cyp2D6 activity) and serum 
leptin, gonadotrophin, and prolactin levels, all of which had 
previously been suggested to be related to PE and SSRI-in-
duced ejaculation delay [7,9,10]. In addition, on the basis 
of the hypothesis of Waldinger et al. [11] that the IELT in 
men with lifelong PE is related to 5-HT1A and/or 5-HT2C re-
ceptor functioning, we investigated the role of 5-HT1A re-
ceptor gene C(-1019)G polymorphism. Owing to the rarity 
of the phenomenon, a small number of patients and con-




Included were patients with complaints of lifelong PE. As 
(nearly) complete absence of any paroxetine-induced ejac-
ulation delay together with absence of ejaculation delay af-
ter another serotonergic antidepressant is an infrequent 
clinical phenomenon as far as we know, we informed 5 
males who had been (unsuccessfully) treated by the last au-
thor before the start of the current study about the purpose 
of the study. All of these patients agreed to participate in 
the current study, which meant that they could not take an 
SSRI or clomipramine for 6 months prior to the start of the 
study. On the other hand, we recruited 8 new patients with 
lifelong PE who after telephone screening were seen at the 
Outpatient Department of Neurosexology of Haga Hospital 
in the Netherlands. All men were informed about the pur-
pose of the current study, which was to investigate factors 
that may contribute to paroxetine-induced ejaculation 
delay. 
All patients included were heterosexual men aged 18 to 
65 years with lifelong PE. All patients had a stable relation-
ship with a female partner. Exclusion criteria were erectile 
dysfunction, alcohol or substance abuse, mental disorders, 
physical illnesses, concomitant medications, a history of 
sexual abuse, serious relationship problems, a history of 
very low intercourse frequency, pregnancy of the partner 
or pregnancy wish in the near future, and possible un-
acceptable risks for occupational hazards owing to side ef-
fects of the study drugs. 
Informed consent was obtained from all patients after 
the study and possible side effects were explained. The 
study was approved by the Hospital Medical Ethical 
Committee and was conducted in accordance with the 
Helsinki Declaration of 1975 as revised in 1983.
2. Assessment and treatment
Lifelong PE was defined according to the International 
Society for Sexual Medicine (ISSM), e.g., a male sexual dys-
function characterized by ejaculation which always or 
nearly always occurs prior to or within about 1 minute of 
vaginal penetration, and the inability to delay ejaculation 
on all or nearly all vaginal penetrations, and negative per-
sonal consequences, such as distress, bother, frustration, 
and/or the avoidance of sexual intimacy [12].
The IELT was defined as the time between the start of 
vaginal intromission and the start of intravaginal ejacu-
lation [13]. Because a placebo response to SSRI-induced 
ejaculation delay has been shown to be less than two folds 
the increase of the geometric mean IELT [1], response to 
treatment in the current study was defined as a fold in-
crease (FI) of the geometric mean IELT higher than 2 
(FI=IELT value at the end of treatment period/IELT value 
at baseline). 
Patients attended the outpatient department approx-
imately 1 month before the start of treatment (first base-
line assessment), on the day before treatment (second base-
line assessment), and at the end of three consecutive series 
of 4 weeks of daily treatment with 10-, 20-, and 30-mg pa-
roxetine, respectively. 
At the first visit, patients were interviewed individually 
Korean J Urol 2014;55:599-607
Paroxetine Nonresponse in Lifelong Premature Ejaculation 601




Age patient, mean±SD 41±8.1 44±6.1
Age partner, mean±SD   35±10.1 39±7.4
Marital status (%)
    Married 57 60
    Divorced - -
    Girlfriend 43 40
    Single - -
Duration relationship (y)   12.7   13.0
Education (%)
    University - -
    Higher 57 -
    Lower 29 50
    Etc. 14 50
SD, standard deviation. 
by the last author and asked for an independent estimation 
of the IELT. A stopwatch and instructions on how to meas-
ure the IELT with the stopwatch were provided. The IELT 
was measured at home over the following 16 weeks. The fe-
male partners had to handle the stopwatch. Patients were 
instructed not to have interrupted intromission or to in-
crease their speed of intercourse. This instruction was 
checked during later visits to the clinic. If intercourse took 
place more than once at the time of IELT measurement, on-
ly the first episode of vaginal penetration with ejaculation 
was included. Patients were not permitted to use condoms 
or topical anaesthetics during the study, and no psycho-
therapeutic interventions were made. 
After a 1-month baseline period, patients received half 
tablets of paroxetine hydrochloride hemihydrate 20 mg for 
4 weeks. The study medication was provided by the 
Hospital Pharmacy Department. The patients were re-
quested to take half a tablet (10 mg) once daily in the morn-
ing in the first month of treatment and one tablet (20 mg) 
daily in the morning in the following 4 weeks. In the last 
month, the patients took 1 tablet of paroxetine 30 mg daily 
in the morning. After each period of 4 weeks, patients re-
turned to the hospital. On that day, blood samples of leptin 
and paroxetine were taken at 4 fixed times in the morning, 
e.g., at 8:30 AM, 9:30 AM, 10:30 AM, and 11:30 AM, 
respectively. At 9:00 AM one tablet of 10-, 20-, or 30-mg pa-
roxetine was taken during the first, second, and third 
month, respectively. At the time of blood sampling and pa-
roxetine intake, the patients were sober and had fasted for 
12 hours. Peripheral venous blood samples were taken by 
the first author. 
3. Laboratory analysis
1) Leptin concentrations
Serum leptin concentrations were assessed with a vali-
dated method of analysis (Human Leptin RIA kit [250 
tubes]; catalog #HL-81K; Human Linco Research Inc., St. 
Charles, MO, USA) with a lower limit of quantification of 
0.5 ng/mL and a variation coefficient that was dependent 
on the serum leptin concentration [8]: 8.3% at 4.9 ng/mL, 
4.6% at 7.2 ng/mL, and 3.6% at 25.6 ng/mL. 
2) Paroxetine concentrations
Serum paroxetine concentrations were assessed with a va-
lidated method of analysis with a lower limit of quantifica-
tion of 3.7 g/L and a variation coefficient of 2.9%. Because 
the concentration of paroxetine is dependent on its metabo-
lism, it should be noted that the metabolism of paroxetine 
has a linear and a nonlinear component [14]. The nonlinear 
component is caused by transversion of paroxetine by 
CYP2D6. CYP2D6 has been investigated on the presence 
of mutations *3, *4, and *6. The CYP2D6*3, *4, and *6 mu-
tations are coding for enzymes that are less active than the 
(wildtype) enzymes [14]. Genotyping of the CYP2D6 en-
zymes was performed by Taqman analysis. Of the CYP2D6 
mutations, the *3, *4, and *6 mutations are most fre-
quently seen in Caucasians [14]. More than 95% of slow me-
tabolizers in a Caucasian population can be determined by 
assessing these mutations [4]. 
3) 5-HT1A receptor gene polymorphism (C-1019G)
For a 50-L polymerase chain reaction (PCR), we used 
about 10 ng of genomic DNA. The primers of the 5-HT1A re-
ceptor gene polymorphism (C-1019G) were as follows: P1 
(5’-GGC TGG ACT GTT AGA TGA TAA CG-3’) and P2 
(5’-GGA AGA AGA CCG AGT GTG TCA T-3’). The under-
lined nucleotide is a mismatch with the 5HT sequence, cre-
ating a restriction site in the PCR product. PCR conditions 
were as follows: 7 minutes at 94oC; 35 cycles of 1 minute 
at 94oC, 1 minute at 59oC, and 1 minute at 72oC; and finally 
7 minutes at 72oC. The size of the amplified product was 
163 bp. Then the PCR product (10 L) was digested with 
BseGII (Fermentas) in a total volume of 15 L for 1 hour 
at 55oC and subsequently analyzed on a 3% agar-
ose/Tris-borate-ethylenediaminetetraacetic acid gel with 
ethidium bromide staining. The fragment obtained for the 
wild-type allele was 163 bp and those for the variant allele 
were 146 and 17 bp. 
4. Statistical analysis
Data analysis was performed with IBM SPSS Statistics 
ver. 19.0 (IBM Co., Armonk, NY, USA). Student t-test was 
performed for the comparison of various concentrations of 
leptin and paroxetine. Regression analysis was performed 
to assess the alterations of leptin concentrations during the 
day and throughout the 16 weeks of the current study. 
Differences were considered significant at p＜0.05.
RESULTS
The characteristics of the patients are shown in Table 1. 
The study included 6 paroxetine nonresponders and 7 
responders. Notably, one of these nonresponders was 
among the newly recruited men. Because this individual 
only appeared to not respond to daily paroxetine treat-
Korean J Urol 2014;55:599-607
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TABLE 2. Baseline IELT, paroxetine-induced fold increase of the 
geometric mean IELT during the 10-, 20-, and 30-mg paroxetine 






    Mean 25.9 38.4
    Geometric mean 16.9 21.7
    Median 20.0 18.2
Paroxetine induced fold 
  increase in IELT 
    10 mg   2.0   1.1
    20 mg   6.6   1.5
    30 mg   8.8   1.7
BMI (kg/m2), mean±SD
    Baseline 27.0±4.0 27.0±0.8
    End study 27.0±4.5 26.5±1.0
IELT, intravaginal ejaculatory latency time; BMI, body mass in-
dex; SD, standard deviation. 
ment, he differed from the 5 previously known men who did 
not respond to paroxetine and another SSRI or clomipra-
mine. No significant differences were found between the 
groups in age, marital status, or duration of relationship. 
Table 2 shows the baseline IELT values, the FIs of the 
geometric mean IELT after the three paroxetine treatment 
periods, and the body mass index (BMI) at baseline and at 
the end of the study. The IELTs were not significantly dif-
ferent between the responders and the nonresponders at 
baseline. All 6 paroxetine nonresponders had a FI of less 
than 2, ranging from 1.1 to 1.7. In contrast, the 7 paroxetine 
responders had a FI of more than 2, ranging from 2 to 8.8 
in relation to the dosage of paroxetine treatment. The num-
ber of intercourses at baseline in the responder and non-
responder groups was 7 and 5, respectively. In the three 
drug treatment periods, the number of intercourses was 5, 
4, and 4 in the responders and 6, 5, and 5 in the non-
responders, respectively. 
In the responders, the FI of the geometric mean IELT 
during the three paroxetine treatment periods was sig-
nificantly different between the 10-, 20-, and 30-mg doses 
(p=0.004) and between the 20- and 30-mg doses (p=0.049). 
In the nonresponders, the FI of the geometric mean IELT 
during the three paroxetine treatments periods was not 
significantly different, e.g., 10 mg versus 20 mg (p=0.43) 
and 20 mg versus 30 mg (p=0.11). Between responders and 
nonresponders, the FI in the geometric mean IELT was sig-
nificantly different after 10-mg (p=0.003), 20-mg (p= 
0.002), and 30-mg (p=0.026), respectively.
BMI at baseline and at the end of study was not sig-
nificantly different in the responders and nonresponders 
(p=0.49).
The serum leptin levels at baseline at 8:30 AM and at 9:30 
AM, 10:30 AM, and 11:30 AM and after each month of treat-
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FIG. 1. The fold increase of the geometric mean intravaginal 
ejaculatory latency time as a function of the paroxetine plasma 
level.
FIG. 2. Fold increase (FI) of the geometric mean intravaginal 
ejaculatory latency time (Y axis) as a function of the serum 
paroxetine dosage (X axis). The second horizontal line repre-
sents a fold increase of 2. In the current study, nonresponse was 
defined as a FI of less than 2, and response was defined as a FI 
of more than 2. On the left side are the FIs of the paroxetine 
nonresponders (GC genotype for the 5-HT1A receptor C-1019 G). 
On the right side, are the FIs of the paroxetine responders (CC 
genotype for the 5-HT1A receptor C-1019 G).
Table 3. Serum leptin levels at baseline were similar in the 
responders and nonresponders, and during the three pa-
roxetine treatment periods they were not significantly dif-
ferent compared with their baseline values. The serum lep-
tin level during the 10-mg paroxetine period was not sig-
nificantly different from baseline (p=0.20), neither was the 
level during the 20-mg (p=0.30) or 30-mg (p=0.31) period. 
Moreover, serum leptin levels were not significantly differ-
ent between responders and nonresponders (p=0.42). 
The serum paroxetine concentrations at 8:30 AM, 9:30 
AM, 10:30 AM, and 11:30 AM after each month of treatment 
with 10-, 20-, and 30-mg of paroxetine are shown in Table 
3. In the responders, serum paroxetine concentrations in-
creased between the 10- and 20-mg doses (p=0.023), be-
tween the 20- and 30-mg doses (p=0.095), and between the 
10- and 30-mg doses (p=0.014). In the nonresponders, se-
rum paroxetine concentrations increased between the 10- 
and 20-mg doses (p=0.064), between the 20- and 30-mg 
doses (p=0.034), and between the 10- and 30-mg doses 
(p=0.025). Between the responders and nonresponders, no 
significant differences were seen between the 10-mg 
(p=0.45), the 20-mg (p=0.33), and the 30-mg dose (p=0.17). 
No association was found between the FI in the geometric 
mean IELT and serum paroxetine levels during the three 
treatment periods, (y=0.1035x + 2.9411/R2=0.066) (Fig. 1). 
Moreover, no association was found between leptin levels 
during the treatment periods and paroxetine serum levels. 
Genetic research showed that all nonresponders to pa-
roxetine treatment were heterozygote (GC genotype) for 
the 5-HT1A receptor C-1019G variation. In contrast, all pa-
roxetine responders had the wildtype (CC) genotype for the 
5-HT1A receptor C-1019 G variation (Fig. 2).
Table 4 shows the serum concentrations of testosterone, 
luteinizing hormone, follicle stimulating hormone, sex 
hormone binding globuline, prolactin, thyroid-stimulating 
hormone (TSH), and T4-free at baseline and at the end of 
8 weeks of paroxetine treatment in both the paroxetine res-
ponders and nonresponders. The table shows that within 
both groups, treatment did not result in significant 
changes in serum concentrations. However, it is remark-
able that serum prolactin levels increased during treat-
ment in the responder group, whereas serum prolactin lev-
els tended to decrease during treatment in the non-
responder group. This change in serum prolactin concen-
trations is represented in Fig. 3. The difference in the 
change in the serum prolactin level in the responder group 
compared with the change in the nonresponder group was 
statistically significant (p= 0.044). However, although this 
phenomenon suggests an association between prolactin re-
lease and paroxetine treatment response and perhaps with 
central 5-HT metabolism, it should not be considered in 
terms of a causal relationship because this remains 
unclear.
DISCUSSION
Given that complete nonresponse to paroxetine and anoth-
er SSRI or clomipramine is rare, we were only able to in-
clude 5 nonresponders who had been unsuccessfully treat-
ed at our outpatient department in the previous 2.6 
(standard deviation, ±3.6) years with paroxetine 20–30 
mg/d, sertraline (n=3), on-demand use of clomipramine 
(n=2), eutectic mixture of local anesthetics crème (n=3), 
and tramadol (n=1). Because one of the newly recruited 
men also showed no response to paroxetine treatment, we 
decided after the end of the study to include this man in the 
nonresponder group. Therefore, the current study involved 
7 responders and 6 nonresponders to daily paroxetine 
treatment. 
Korean J Urol 2014;55:599-607
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TABLE 4. Endocrinological parameters in responders and nonresponders
Parameter  Baseline,  Baseline, SD Week 8, mean Week 8, SD p-valuea
Nonresponders
    FSH (U/L)
    LH (U/L)
    Prolactin (mU/L)
    SHBG (nmol/L)
    T4 free (pmol/L)
    Testosterone (nmol/L)
    TSH (mU/L)
Responders
    FSH (U/L)
    LH (U/L)
    Prolactin (mU/L)
    SHBG (nmol/L)
    T4 free (pmol/L)
    Testosterone (nmol/L)







































































SD, standard deviation; FSH, follicle stimulating hormone; LH, luteinizing hormone; SHBG, sex hormone binding globuline;  TSH, 
thyroid-stimulating hormone.
a:Baseline vs. week 8.
FIG. 3. Paroxetine-induced serum prolactin concentration 
changes in men with lifelong premature ejaculation. In the 
paroxetine nonresponders, prolactin concentrations tend to 
reduce, whereas in paroxetine responders, prolactin concen-
trations increased. 
A clear dose-effect relationship was found in the res-
ponder group, with the highest FI (8.8) of the geometric 
mean IELT in men using 30-mg paroxetine compared with 
those using 10-mg paroxetine (FI, 2.0). At baseline (e.g., 
8:30 AM) the serum concentrations of paroxetine in both 
the responders and the nonresponders were similar at the 
start of paroxetine treatment. In both the responders and 
the nonresponders, the serum concentration of paroxetine 
increased with increasing dosage. No significant differ-
ences in serum levels at the different dosages of paroxetine 
were found throughout the whole period of study between 
the responders and nonresponders. Therefore, it may be 
concluded that in the nonresponders, increasing serum 
levels of paroxetine did not result in a clinically relevant 
ejaculation delay even though the serum paroxetine levels 
were similar between the responders and nonresponders. 
Notably, because serum levels of leptin were not asso-
ciated with the three different dosages of paroxetine, and 
remained similar in the responders and nonresponders 
throughout the whole study period, it may also be con-
cluded that the paroxetine-induced ejaculation delay was 
not associated with the serum leptin level. In this respect, 
it should be emphasized that at baseline, serum leptin lev-
els were similar in responders and nonresponders and were 
within the normal range (3.8±1.8 ng/mL) of males with a 
BMI of 18 to 25 kg/m2 [14]. Notably, the BMI of both the res-
ponders and the nonresponders was similar at baseline and 
at the end of the study. 
Importantly, in both responders and nonresponders, the 
serum leptin level was not associated with the serum pa-
roxetine level and did not show any association with the FI 
of the geometric mean IELT. 
In the current study, Cyp2D6 genotypes were inves-
tigated by measuring *3, *4, *6 and ultraextensive 
metabolism. There were no patients with ultraextensive 
metabolism. The majority of men had the Cyp2D6*1 muta-
tion (homozygote wildtype), but there were two men with 
the Cyp2D6 *3 and *4 mutations, respectively. In other 
words, in these men there is less Cyp2D6 activity, which 
may result in higher paroxetine plasma levels. Indeed, it 
was found that while using 30 mg of paroxetine per day, 
these men had a higher serum paroxetine level than did 
men without these Cyp2D6 mutations. However, because 
the number of patients was low, we cannot make any con-
clusions about the significance of this higher paroxetine 
level in relation to these mutations. Moreover, the IELTs 
of these men were not significantly different, and the BMI 
Korean J Urol 2014;55:599-607
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and the serum leptin level also did not differ significantly 
compared with values in men without the Cyp2D6 
mutation. In other words, the IELT in these men was not 
dependent on the serum paroxetine level, the serum leptin 
level, or BMI.
Interestingly, we found that the 6 paroxetine non-
responders were heterozygous (GC genotype) for the 
5-HT1A receptor C-1019G variation, whereas the 7 res-
ponders had the wildtype (CC) genotype. However, note 
that these findings could be the result of a selection bias, 
because before the onset of the study, we purposely selected 
5 nonresponders to previous paroxetine and other SSRI 
and clomipramine treatment. Intriguingly, although the 
number of patients in both groups was very low, a similar 
finding in responders and nonresponders was not present 
in our previous study investigating the 5-HTTLPR poly-
morphism and paroxetine-induced ejaculation delay in 54 
men with lifelong PE, in which nonresponse to parox-
etine-induced ejaculation delay was present in 20% of men 
[2]. Because the 5-HT1A receptor is important in mediating 
ejaculation, the current finding warrants further research 
of this phenomenon in larger group of men with lifelong PE. 
Apart from the aforementioned difference in 5-HT1A re-
ceptor gene polymorphism in paroxetine responders and 
nonresponders, the current study shows another interest-
ing difference between the groups. The serum prolactin lev-
el increased in the responders, whereas it tended to de-
crease in the nonresponders. Although the prolactin in-
crease in the responders was not significantly different 
compared with the baseline values in the responder group, 
and the prolactin decrease in the nonresponders was not 
significantly different compared with the baseline values 
in the nonresponder group, the change (+delta) in the pro-
lactin levels in the responder group was significantly dif-
ferent (p=0.044) from the change (–delta) in the prolactin 
levels in the nonresponder group. Although caution is war-
ranted when interpreting this finding in light of the small 
number of patients, the phenomenon is intriguing and war-
rants further research in a larger group of men.
The aforementioned results suggest that in the current 
group of men with lifelong PE, (1) neither lifelong PE nor 
the duration of the IELT is associated with serum leptin 
levels, (2) the serum leptin level is within the range of the 
normal population, (3) paroxetine treatment-induced ejac-
ulation delay is not associated with serum leptin levels, (4) 
paroxetine treatment-induced ejaculation delay is not 
solely related to serum paroxetine levels, (5) paroxetine 
treatment-induced ejaculation delay is not associated to 
serum leptin levels, and (6) nonresponse to paroxetine 
treatment is not related to paroxetine serum levels, serum 
leptin levels, or the patients’ BMI. Instead, it may well be 
that paroxetine-induced ejaculation delay and non-
response to paroxetine treatment is associated with 5-HT1A 
receptor C-1019 G polymorphism or prolactin metabolism 
or underlying mechanisms of action.
The strengths of the current study were the strict sam-
pling protocol, the measurement of IELT with a stopwatch 
during a baseline period and during three consecutive 
4-week daily paroxetine treatment periods, and the in-
clusion of SSRI (including paroxetine) nonresponders and 
paroxetine responders. Another strength was that blood 
sampling was performed at four different fixed time points 
in the morning after 12 hours of fasting, at the onset of and 
after 4 weeks of the baseline period, and after three consec-
utive daily paroxetine treatment periods with 10-, 20-, and 
30-mg paroxetine hemihydrate. Last, serum paroxetine 
levels and serum leptin, prolactin, and gonadotrophin lev-
els were assessed in relation to the three different dosages 
of paroxetine, Cyp2D6 assessment, and 5-HT1A receptor 
polymorphism genotyping. However, a limitation of the 
current study was the small number of patients. 
Although this is the first study investigating SSRI non-
response in men with lifelong PE, our findings regarding 
serum leptin levels are not in line with three previous stud-
ies on leptin in relation to PE (Table 4). For example, in 
2002, Atmaca et al. [9] reported a high serum leptin level 
of 25.7±3.9 ng/mL in 15 Turkish men with PE compared 
with 7.9 ±2.1 ng/mL in 15 healthy controls, after adjust-
ment for BMI and age. In a second study, Atmaca et al. [7] 
reported significantly decreased leptin levels (8.3±2.8 
ng/mL) in 15 men with PE after 8 weeks of daily 30.7 ± 9.3 
mg citalopram treatment compared with baseline values 
(23.9±5.3 ng/mL). Atmaca et al. [7] therefore suggested 
that PE is associated with increased serum leptin levels 
and that citalopram treatment induces a decrease in leptin. 
However, although it was mentioned in the latter study 
that the patients had the same weight at the end of the 
study, the BMI at the end of the study was not reported. 
It therefore remains rather unclear whether the decreased 
leptin level after citalopram treatment was related to a 
change in the BMI of the PE patients. Notably, in contrast 
to their first study, the second study of Atmaca et al. [7] re-
ported a high serum leptin concentration in their control 
males (24.2±3.8 ng/mL). This finding of Atmaca et al. [7] 
also contrasts the findings of Nikoobakht et al. [10], who 
in 46 Iranian men with PE found a normal but higher base-
line serum leptin level (8.3±3 ng/mL) than in a control 
group of 44 men with nephrolithiasis (3.3±1 ng/mL). 
In our current study, all patients had leptin levels that 
had a normal value compared to a standard control group. 
Moreover, our patients, both the responders and the non-
responders, had the same leptin levels, both at baseline and 
at the end of the three paroxetine treatment periods. 
Indeed, in our study, both the responders and the non-
responders had an identical BMI at the start and at the end 
of the study. Thus, there is no reason to believe that lifelong 
PE or the IELT is related to weight or serum leptin 
concentrations. Neither is there reason to believe that pa-
roxetine treatment influences or is influenced by serum 
leptin levels. In other words, on the basis of our study, in 
which serum leptin and testosterone levels, other gonado-
trophic parameters, TSH, T4-free, and BMI remained ho-
mogeneous throughout paroxetine treatment in both res-
ponders and nonresponders, serum leptin levels cannot be 
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considered a biological marker of PE as has been suggested 
by Atmaca et al. [7,9] and Nikoobakht et al. [10]. On the con-
trary, many questions remain regarding leptin that must 
be investigated in the context of lifelong PE. 
As is summarized in Table 5, it is of note that the four 
studies on leptin, including the current study, used differ-
ent leptin kits. In the current study, a radioimmunoassay 
(RIA) method, specific for human leptin, was used, whereas 
Nikoobakht et al. [10] used an enzyme-linked immune as-
say method, specific for human leptin. In contrast, Atmaca 
et al. [7,9] used an RIA method specific for rat leptin to 
measure human serum leptin concentrations. Although 
our human kit has a cross-reactivity of 100% with human 
leptin, the cross-reactivity of the kit used by Atmaca et al. 
[7,9] is only 40% [15]. However, whether the use of different 
leptin kits contributed to the different findings of Atmaca 
et al. [7,9], Nikoobakht et al. [10], and the current study re-
mains unknown. 
Another explanation for the different findings may be re-
lated to different testosterone levels of the included 
patients. High testosterone in males has been reported to 
be associated with low serum leptin levels [8]. Because se-
rum testosterone was not measured in any of the afore-
mentioned studies, it cannot be excluded that the differ-
ences between the four studies are related to differences in 
serum testosterone levels. It is therefore recommended 
that in future studies on PE and leptin, serum testosterone 
be measured. 
CONCLUSIONS
Using a very strict and elaborate sampling protocol at dif-
ferent daily doses of paroxetine, we found no explanation 
for the absence of paroxetine-induced ejaculation delay in 
six men with lifelong PE. Moreover, we found no indication 
that the level of leptin is associated with the presence of life-
long PE, the dosage or duration of daily paroxetine treat-
ment, the serum level of paroxetine, or the duration of the 
IELT at baseline or during paroxetine treatment. In addi-
tion, we found no evidence that daily use of paroxetine in-
fluences plasma leptin levels in either responders or non-
responders to daily paroxetine treatment. 
Although it was found that increasing daily doses of pa-
roxetine were associated with a stronger ejaculation delay, 
we found no association between serum paroxetine concen-
trations and paroxetine-induced FI of the geometric mean 
IELT. However, we did find that serum concentrations of 
paroxetine were higher in two men with the Cyp2D6*3 and 
*4 variations, respectively. However, because there is no 
relation between the serum paroxetine concentration and 
the IELT, this genotype for paroxetine metabolism is not 
relevant for paroxetine-induced ejaculation delay in the 
current study. Interestingly, in the current group of men, 
we found two intriguing phenomenons. First, all parox-
etine nonresponders were heterozygous (GC genotype) for 
the 5-HT1A receptor C-1019G variation, whereas all res-
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though we have argued that these results may be related 
to a selection bias, further research in a larger group of men 
with lifelong PE is warranted to investigate whether this 
polymorphism plays a role in paroxetine treatment 
nonresponse. Second, serum prolactin levels increased in 
the paroxetine responders, whereas they tended to de-
crease in the paroxetine nonresponders. The change in pro-
lactin serum level after paroxetine treatment in the res-
ponders was significantly different compared with the pro-
lactin serum level change in the nonresponders. This phe-
nomenon deserves further investigation in future studies. 
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